Placebo News and Research

RSS

Study examines potential health benefits of DCT

Imagine your delight while enjoying your favorite Mexican food - perhaps a fully loaded bean burrito topped with an ample supply of thinly sliced jalepeño peppers. What happens when you bite into a few more peppers than you bargained for? Does this thought conjure up the thought of a little heat? Perhaps even a bit of sweat on the brow? Indeed, food scientists can tell you that hot peppers contain a substance called capsaicin that not only adds spice to our foods but can actually cause your body to heat up.

28 Apr 2010

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Patients with diabetic nephropathy (kidney disease caused by diabetes) who received high dose B-vitamin therapy experienced a more rapid decline in kidney function and had a higher rate of heart attack and stroke than patients who received placebo, according to a study in the April 28 issue of JAMA.

28 Apr 2010

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, announced the successful conclusion of the Company's second Phase I/II clinical trial of the Multimeric-001 Universal Influenza Vaccine.

28 Apr 2010

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

Icagen, Inc. today provided an update on clinical development plans for ICA-105665, the Company's novel drug candidate for the treatment of epilepsy and pain.

28 Apr 2010

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.

28 Apr 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

ASPO meeting to focus on children's ear, nose and throat health

The American Society of Pediatric Otolaryngology will hold its annual meeting, April 30 - May 2, during the 2010 Combined Otolaryngology Spring Meetings - a joint meeting of eight otolaryngological societies in Las Vegas, NV.

27 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that it has filed a request for an FDA meeting to advance the URG101 clinical program and mutually agreed with Oceana Therapeutics, Inc. to terminate their Consulting Agreement effective immediately.

24 Apr 2010

Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress

Boston-based medical technology firm Gelesis, Inc. unveiled its capsulated device Attiva™, and presented data showing that Attiva™ significantly increased the post-meal feeling of satiety and reduced hunger between meals in obese patients. This data was presented today at the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting & Clinical Congress.

23 Apr 2010

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

Vical Incorporated announced today that the company's TransVax cytomegalovirus vaccine elicited sustained increases in both cellular and antibody immune responses compared with placebo through the final 12-month follow-up in an ongoing Phase 2 trial in hematopoietic cell transplant recipients.

22 Apr 2010

Increase in mammographic density associated with increase of breast cancer in EPT study participants

An increase in breast density appears to be the culprit behind an increase of breast cancer found in women participating in the estrogen and progestin therapy study, a part of the Women's Health Initiative (WHI). That is the finding of a new WHI analysis led by Celia Byrne, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center, and presented during the AACR 101st Annual Meeting 2010 in Washington, DC.

22 Apr 2010

Mammographic density is one of the strongest predictors of breast cancer risk: Researchers

Women who have a breast density of 75 percent or higher on a mammogram have a risk of breast cancer that is four to five times greater than that of women with little or no density, making mammographic breast density one of the strongest biomarkers of breast cancer risk.

22 Apr 2010

OPAL study: Fish oil supplements offer no benefits for cognitive function in older people

The largest ever trial of fish oil supplements has found no evidence that they offer benefits for cognitive function in older people.

22 Apr 2010

New treatment modalities for RCC

Renal cell carcinoma accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

21 Apr 2010

IMPACT trial shows improvement in OS for metastatic CRPC

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

21 Apr 2010

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix' internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.

20 Apr 2010

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.

20 Apr 2010

Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting

Teva Pharmaceutical Industries Ltd. today announced results from the placebo group analyses of the ADAGIO study that were presented at the 62nd Annual Meeting of the American Academy of Neurology. The ADAGIO study stands out from other Parkinson's disease trials as it is the largest clinical study conducted in patients who were still in the very early stages of their disease course (average time from PD diagnosis of 4.5 months).

20 Apr 2010

On-going phase II trial of octagam in AD to be discussed at ICAD 2010

The on-going phase II trial on Octapharma's 10% intravenous immunoglobulin octagam®10% will be a topic at the up-coming International Conference on Alzheimer's Disease to take place in Honolulu, Hawaii from July 10 to 15.

20 Apr 2010

Placebo News and Research

Study examines potential health benefits of DCT

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

ASPO meeting to focus on children's ear, nose and throat health

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress

Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress

Increase in mammographic density associated with increase of breast cancer in EPT study participants

Mammographic density is one of the strongest predictors of breast cancer risk: Researchers

OPAL study: Fish oil supplements offer no benefits for cognitive function in older people

New treatment modalities for RCC

IMPACT trial shows improvement in OS for metastatic CRPC

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting

On-going phase II trial of octagam in AD to be discussed at ICAD 2010

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News